Table 2.
Selection of ongoing clinical trials of systemic therapy in meningioma
| Clinical trial identification | Drug | Drug class | Main inclusion criterion | Status (effective 12/07/2022) |
|---|---|---|---|---|
| NCT03071874 (phase 2) | Vistusertib | mTOR inhibitor | Recurrent or progressing WHO grade 2–3 meningioma | Active, not recruiting |
| NCT02523014 (phase 2) |
- GSK2256098 - Abemaciclib - Capivasertib - Vismodegib |
- FAK inhibitor - CDK4/6 inhibitor - AKT inhibitor - SHH inhibitor |
Progressing WHO grade 1–3 meningioma | Recruiting |
| NCT03631953 (phase 1) | Alpelisib + trametinib | PI3K inhibitor + MEK inhbitor | Progressing WHO grade 1–3 meningioma | Recruiting |
| NCT03220646 (phase 2) | Abemaciclib | CDK4/6 inhibitor | Recurrent primary brain tumors of all grades (including glioma, meningioma, ependymoma, primary central nervous system lymphoma) | Active, not recruiting |
| NCT01324635 (phase 1) | Panobinostat (+ stereotactic radiation) | Histone deacetylase inhibitor | Recurrent gliomas, high-grade meningiomas, and brain metastases | Terminated, no results published |
| NCT03604978 (phase 1/2) | Nivolumab ± ipilimumab (+ stereotactic radiosurgery) | monoclonal anti-PD-1 and anti-CTLA-4 antibodies | Recurrent WHO grade 2–3 meningioma | Recruiting |
| NCT02648997 (phase 2) |
Nivolumab monotherapy (cohort 1) Nivolumab + ipilimumab after radiation (cohort 2) |
monoclonal anti-PD-1 and anti-CTLA-4 antibodies | Recurrent/progressive WHO grade 2–3 meningioma | Recruiting |
| NCT03173950 (phase 2) | Nivolumab | monoclonal anti-PD-1 antibody | Recurrent rare primary brain tumors (including WHO grade 2–3 meningioma, medulloblastoma, ependymoma, pineal region and choroid plexus tumors) | Recruiting |
| NCT04659811 (phase 2) | Pembrolizumab (+ stereotactic radiosurgery) | monoclonal anti-PD-1 antibody | Recurrent WHO grade 1–3 meningioma | Recruiting |
| NCT03279692 (phase 2) | Pembrolizumab | monoclonal anti-PD-1 antibody | Recurrent WHO grade 2–3 meningioma | Active, not recruiting |
| NCT03016091 (phase 2) | Pembrolizumab | monoclonal anti-PD-1 antibody | Recurrent WHO grade 2–3 meningioma or hemangiopericytoma | Unknown |
| NCT03267836 (phase 1) | Avelumab (neoadjuvant in combination with proton radiation therapy followed by surgery) | monoclonal anti-PD-L1 antibody | Recurrent or progressive WHO grade 1–3 meningioma | Active, not recruiting |